Clinical Edge Journal Scan

Oligoarticular PsA similar to polyarticular PsA with few exceptions


 

Key clinical point: Oligoarticular psoriatic arthritis (PsA) is similar to polyarticular disease. However, involvement of lower extremity small joint had the highest chances of polyarticular presentation, whereas low Short Form-36 (SF-36) Mental Component Summary (MCS) score was significantly associated with progression from oligoarthritis to polyarthritis.

Major finding: Demographics and clinical characteristics were similar between the oligoarticular and polyarticular PsA groups. However, polyarticular PsA was associated with higher odds of lower extremity small joints (odds ratio, 17.15; P < .001). Among patients with oligoarticular PsA, 39% developed polyarticular PsA with lower SF-36 MCS being the only predictor for progression (hazard ratio, 0.97; P = .01).

Study details: Findings are from a longitudinal study including 407 patients with PsA who entered the University of Toronto PsA clinic within 12 months of diagnosis between 1978 and 2018, of which 47% presented with oligoarthritis and 53% with polyarthritis.

Disclosures: The University of Toronto PsA program was funded by the Krembil Foundation. The authors declared no conflict of interests.

Source: Gladman DD et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210434 .

Recommended Reading

HBV screening often incomplete or forgone when starting tocilizumab, tofacitinib
MDedge Rheumatology
Western diet promoted skin, joint inflammation in preclinical study
MDedge Rheumatology
Psoriatic arthritis health care costs continue to rise over time
MDedge Rheumatology
Bimekizumab approved in Europe for psoriasis treatment
MDedge Rheumatology
PsA: Guselkumab demonstrates clinically meaningful and sustained improvement in fatigue
MDedge Rheumatology
Burden of psoriasis is mild in early PsA but impacts HRQoL
MDedge Rheumatology
Treating skin with biologics may reduce risk of developing PsA in patients with psoriasis
MDedge Rheumatology
JAK inhibitors safe and effective over placebo for PsA
MDedge Rheumatology
Secukinumab provides low radiographic progression over 2 years in patients with PsA
MDedge Rheumatology
Secukinumab effective for PsA, with high patient satisfaction in the real world
MDedge Rheumatology